Zeitschrift für Rheumatologie

, Volume 66, Issue 5, pp 441–443 | Cite as

Mycophenolat Mofetil als Remissionsinduktion bei M. Wegener

Klinische Studien kurzgefasst

Mycophenolate mofetil for induction of remission in Wegener’s granulomatosis

Literatur

  1. 1.
    Groot K de, Rasmussen N, Bacon PA et al. (2005) Randomised trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vascultits. Arthritis Rheum 52: 2461–2469PubMedCrossRefGoogle Scholar
  2. 2.
    Omdal R, Wildhagen K, Hansen T et al. (2005) Anti-CD20 therapy of tretment-resistant Wegener’s granulomatosis: favorable but temporary response. Scand J Rheumatol 34: 229–232PubMedCrossRefGoogle Scholar
  3. 3.
    Smith KG, Jones RB, Burns SM, Jayne DR (2006) Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 54: 2970–2982PubMedCrossRefGoogle Scholar
  4. 4.
    Birck R, Warnatz K, Lorenz HM et al. (2003) 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 14: 440–447PubMedCrossRefGoogle Scholar
  5. 5.
    Benenson E, Fries JW, Heilig B et al. (2005) High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegener’s granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide. Clin Rheumatol 24: 251–257PubMedCrossRefGoogle Scholar
  6. 6.
    Jayne DR, Chapel H, Adu D et al. (2000) Intravenous immunoglobulin for ANCA associated systemic vasculitis with persistent disease activity. QJM 93: 433–439PubMedCrossRefGoogle Scholar
  7. 7.
    Metzler C, Fink C, Lamprecht P et al. (2004) Maintenance of remisison with leflunomide in Wegener’s granulomatosis. Rheumatology 43: 315–320PubMedCrossRefGoogle Scholar
  8. 8.
    Henes JC, Fritz J, Koch S et al. (2007) Rituximab for treatment-resistant extensive Wegener’s granulomatosis – additive effects of a maintenance treatment with leflunomide. Clin Rheumatol [Epub ahead of print, May 15]Google Scholar
  9. 9.
    Koldingsness W, Nossent JC (2003) Baseline features and initial treatment as predictors of remisison or relapse in Wegener’s granulomatosis. J Rheumatol 30: 80–88Google Scholar

Copyright information

© Springer Medizin Verlag 2007

Authors and Affiliations

  1. 1.Abteilung Innere Medizin II (Hämatologie, Onkologie, Immunologie, Rheumatologie, Pulmologie)Medizinische Universitätsklinik TübingenTübingenDeutschland

Personalised recommendations